## Claims

1) An isolated cysteine engineered bispecific FN3 molecule comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 266, 268, and 270, wherein the bispecific molecule further comprises a half-life extending moiety.

2) The isolated cysteine engineered bispecific molecule of claim 1, wherein the molecule is chemically-conjugated to a thiol-reactive reagent.

3) The isolated cysteine engineered bispecific molecule of claim 2, wherein the thiol-reactive reagent is a maleimide moiety.

4) The isolated cysteine engineered bispecific molecule of claim 3, wherein the maleimide moiety is selected from the group consisting of NEM, PEG24-maleimide, fluorescein maleimide, MMAE, and MMAF.

5) The isolated cysteine engineered bispecific molecule of claim 1, wherein the half-life extending moiety is albumin, an albumin binding molecule, a polyethylene glycol (PEG), or at least a portion of an Fc region of an immunoglobulin.

6) The isolated cysteine engineered bispecific molecule of claim 6, wherein the albumin binding molecule is an albumin binding FN3 domain.

7) The isolated cysteine engineered bispecific molecule of claim 7, wherein the albumin binding FN3 domain comprises the amino acid sequence of SEQ ID NO:274.

8) The isolated cysteine engineered bispecific FN3 molecule of claim 8, wherein the amino acid sequence is selected from the group consisting of SEQ ID NOS: 267, 269, and 271.